Thaysen has had to deal with orchestrating Illumina’s comeback strategy and the loose ends related to unwinding the company’s failed $7.1 billion acquisition of Grail. The early stage blood ...

11 analysts have expressed a variety of opinions on Illumina ILMN over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

China accounts for roughly 7% of Illumina’s total annual revenue, or about $300 million, though it has continued to decline in that market in recent quarters. Puneet Souda, a research analyst ...

China accounts for about 7% of Illumina's sales. Gene sequencers help determine the sequence of DNA or RNA, allowing scientists to study genetic variations associated with diseases and diagnose ...

Here are the biggest headlines of the day in the latest Market Minute. Illumina (ILMN) shares have recouped their losses. The stock had fallen after China banned it from exporting its gene ...

Illumina is the world’s leading producer of gene-sequencing machines and counts on China for 7 percent of its sales. Beijing also said it took action against dozens of other companies from the ...

In 2024, the UCITS C-share USD returned 14.7% net of fees, while the MSCI ACWI ... Brown Advisors Global Leaders Strategy emphasized stocks such as Illumina, Inc. (NASDAQ:ILMN).

BEIJING’S surprise move to blacklist Illumina has unleashed a frenzy among the US firm ... The US company, which made around 7 per cent of its revenue in China last year, has steadily lost market ...

In 2020, Illumina announced that it had reached an agreement with Grail for an acquisition worth $7.1 billion. Illumina completed the deal just under a year later, bringing Grail back under its ...